| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 38.45M | 55.66M | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M | 178.96M |
| Revenue Growth % | - | 0.45% | 0.53% | 0.16% | 0.57% | 0.2% | -0.08% | 0.05% |
| Cost of Goods Sold | 15.68M | 19.67M | 22.27M | 22.53M | 49.3M | 57.91M | 75.55M | 72.08M |
| COGS % of Revenue | 0.41% | 0.35% | 0.26% | 0.23% | 0.32% | 0.31% | 0.44% | 0.4% |
| Gross Profit | 22.77M | 35.99M | 62.8M | 75.85M | 105.04M | 127.4M | 94.72M | 106.88M |
| Gross Margin % | 0.59% | 0.65% | 0.74% | 0.77% | 0.68% | 0.69% | 0.56% | 0.6% |
| Gross Profit Growth % | - | 0.58% | 0.74% | 0.21% | 0.38% | 0.21% | -0.26% | 0.13% |
| Operating Expenses | 66.4M | 85.75M | 141.19M | 228.67M | 314.01M | 327.58M | 321.76M | 269.43M |
| OpEx % of Revenue | 1.73% | 1.54% | 1.66% | 2.32% | 2.03% | 1.77% | 1.89% | 1.51% |
| Selling, General & Admin | 32.71M | 44.9M | 68.78M | 110.89M | 169.97M | 184.13M | 172.51M | 157.56M |
| SG&A % of Revenue | 0.85% | 0.81% | 0.81% | 1.13% | 1.1% | 0.99% | 1.01% | 0.88% |
| Research & Development | 32M | 39.16M | 70.7M | 116.07M | 142.34M | 141.76M | 122.12M | 102.95M |
| R&D % of Revenue | 0.83% | 0.7% | 0.83% | 1.18% | 0.92% | 0.76% | 0.72% | 0.58% |
| Other Operating Expenses | 1.69M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 27.13M | 8.91M |
| Operating Income | -44.48M | -49.76M | -78.39M | -152.82M | -208.97M | -200.19M | -227.03M | -162.55M |
| Operating Margin % | -1.16% | -0.89% | -0.92% | -1.55% | -1.35% | -1.08% | -1.33% | -0.91% |
| Operating Income Growth % | - | -0.12% | -0.58% | -0.95% | -0.37% | 0.04% | -0.13% | 0.28% |
| EBITDA | -38.68M | -43.76M | -70.6M | -144.34M | -195.01M | -179.27M | -204.8M | -143.29M |
| EBITDA Margin % | -1.01% | -0.79% | -0.83% | -1.47% | -1.26% | -0.97% | -1.2% | -0.8% |
| EBITDA Growth % | - | -0.13% | -0.61% | -1.04% | -0.35% | 0.08% | -0.14% | 0.3% |
| D&A (Non-Cash Add-back) | 5.8M | 6M | 7.79M | 8.47M | 13.95M | 20.92M | 22.23M | 19.26M |
| EBIT | -43.63M | -49.76M | -78.39M | -152.82M | -207.3M | -196.13M | -211.5M | -148.01M |
| Net Interest Income | 1.64M | 3.31M | 9.79M | 6.59M | 1.67M | -182K | 1.73M | 2.95M |
| Interest Income | 1.64M | 3.31M | 9.79M | 6.59M | 1.67M | 4.06M | 15.53M | 14.53M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 4.24M | 13.8M | 11.58M |
| Other Income/Expense | 1.64M | 3.31M | 9.79M | 6.59M | 1.67M | -182K | 1.73M | 2.95M |
| Pretax Income | -42.83M | -46.45M | -68.61M | -146.23M | -207.3M | -200.37M | -225.3M | -159.59M |
| Pretax Margin % | -1.11% | -0.83% | -0.81% | -1.49% | -1.34% | -1.08% | -1.32% | -0.89% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -42.83M | -46.45M | -68.61M | -146.23M | -207.28M | -200.19M | -225.25M | -159.49M |
| Net Margin % | -1.11% | -0.83% | -0.81% | -1.49% | -1.34% | -1.08% | -1.32% | -0.89% |
| Net Income Growth % | - | -0.08% | -0.48% | -1.13% | -0.42% | 0.03% | -0.13% | 0.29% |
| Net Income (Continuing) | -42.83M | -46.45M | -68.61M | -146.23M | -207.3M | -200.37M | -225.3M | -159.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 110K | -67K | -121K | -224K |
| EPS (Diluted) | -0.41 | -0.44 | -0.47 | -1.06 | -1.46 | -1.00 | -1.56 | -1.08 |
| EPS Growth % | - | -0.07% | -0.07% | -1.26% | -0.38% | 0.32% | -0.56% | 0.31% |
| EPS (Basic) | -0.41 | -0.44 | -0.47 | -1.06 | -1.46 | -1.00 | -1.56 | -1.08 |
| Diluted Shares Outstanding | 105.43M | 105.43M | 124.34M | 131.22M | 140.35M | 142.52M | 144.38M | 147.1M |
| Basic Shares Outstanding | 105.43M | 105.43M | 124.34M | 131.22M | 140.35M | 142.52M | 144.38M | 147.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 205.25M | 180.72M | 612.69M | 726.91M | 402.75M | 562.15M | 410.19M | 283.75M |
| Cash & Short-Term Investments | 192.15M | 165.02M | 576.87M | 688.27M | 353.06M | 498.2M | 346.4M | 222.29M |
| Cash Only | 85.31M | 55.03M | 96.58M | 123.44M | 139.06M | 90.03M | 65.06M | 47.92M |
| Short-Term Investments | 106.84M | 109.99M | 480.29M | 564.83M | 214M | 408.17M | 281.34M | 174.37M |
| Accounts Receivable | 5.58M | 4.81M | 12.68M | 10.05M | 17.41M | 40.06M | 37.97M | 41.73M |
| Days Sales Outstanding | 52.99 | 31.52 | 54.39 | 37.27 | 41.17 | 78.9 | 81.39 | 85.11 |
| Inventory | 4.79M | 7.84M | 9.07M | 14.06M | 19.26M | 14.45M | 14.45M | 8.44M |
| Days Inventory Outstanding | 111.55 | 145.46 | 148.61 | 227.83 | 142.61 | 91.1 | 69.8 | 42.74 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 9.44M | 11.37M | 11.29M |
| Total Non-Current Assets | 157.24M | 151.97M | 299.61M | 389.5M | 520.6M | 294.47M | 250.95M | 255.62M |
| Property, Plant & Equipment | 13.95M | 19.13M | 60.35M | 139.04M | 172.94M | 164.21M | 120.32M | 94.38M |
| Fixed Asset Turnover | 2.76x | 2.91x | 1.41x | 0.71x | 0.89x | 1.13x | 1.42x | 1.90x |
| Goodwill | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M |
| Intangible Assets | 15.32M | 13.63M | 11.93M | 10.22M | 8.53M | 6.83M | 5.13M | 3.42M |
| Long-Term Investments | 8.9M | 247K | 105.44M | 118.53M | 217.15M | 0 | 0 | 33.66M |
| Other Non-Current Assets | 86K | 247K | 2.92M | 2.74M | 3.01M | 4.46M | 6.52M | 5.18M |
| Total Assets | 362.49M | 332.69M | 912.3M | 1.12B | 923.34M | 856.62M | 661.13M | 539.38M |
| Asset Turnover | 0.11x | 0.17x | 0.09x | 0.09x | 0.17x | 0.22x | 0.26x | 0.33x |
| Asset Growth % | - | -0.08% | 1.74% | 0.22% | -0.17% | -0.07% | -0.23% | -0.18% |
| Total Current Liabilities | 21M | 22.8M | 78.31M | 105.2M | 113.81M | 109.79M | 88.02M | 98.05M |
| Accounts Payable | 1.96M | 1.79M | 4.45M | 3.24M | 3.31M | 8.08M | 7.72M | 7.26M |
| Days Payables Outstanding | 45.72 | 33.27 | 72.97 | 52.44 | 24.48 | 50.95 | 37.29 | 36.79 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.93M | 3.67M | 8.49M | 11.95M | 15.64M | 15.94M | 13.69M | 16.7M |
| Current Ratio | 9.77x | 7.93x | 7.82x | 6.91x | 3.54x | 5.12x | 4.66x | 2.89x |
| Quick Ratio | 9.54x | 7.58x | 7.71x | 6.78x | 3.37x | 4.99x | 4.50x | 2.81x |
| Cash Conversion Cycle | 118.82 | 143.7 | 130.03 | 212.66 | 159.3 | 119.04 | 113.9 | 91.06 |
| Total Non-Current Liabilities | 566.1M | 568M | 262.95M | 267.95M | 205.44M | 282.73M | 264.84M | 238.84M |
| Long-Term Debt | 0 | 561.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 36.61M | 104.33M | 106.69M | 98.77M | 89.39M | 79.15M |
| Deferred Tax Liabilities | 0 | -561.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 566.1M | 6.1M | 7.01M | 0 | 0 | 125.36M | 130.66M | 132.43M |
| Total Liabilities | 587.11M | 590.8M | 341.26M | 373.15M | 319.24M | 392.52M | 352.86M | 336.89M |
| Total Debt | 561.67M | 561.19M | 36.61M | 107.86M | 111.74M | 108M | 98.77M | 89.39M |
| Net Debt | 476.37M | 506.16M | -59.97M | -15.57M | -27.32M | 17.97M | 33.71M | 41.47M |
| Debt / Equity | - | - | 0.06x | 0.15x | 0.18x | 0.23x | 0.32x | 0.44x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -47.24x | -16.45x | -14.04x |
| Total Equity | -224.62M | -258.11M | 571.04M | 743.27M | 604.1M | 464.1M | 308.28M | 202.49M |
| Equity Growth % | - | -0.15% | 3.21% | 0.3% | -0.19% | -0.23% | -0.34% | -0.34% |
| Book Value per Share | -2.13 | -2.45 | 4.59 | 5.66 | 4.30 | 3.26 | 2.14 | 1.38 |
| Total Shareholders' Equity | -224.62M | -258.11M | 571.04M | 743.27M | 603.99M | 464.17M | 308.4M | 202.71M |
| Common Stock | 1K | 1K | 12K | 14K | 14K | 14K | 14K | 14K |
| Retained Earnings | -249.42M | -295.91M | -365.48M | -511.61M | -718.89M | -919.08M | -1.14B | -1.3B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -166K | -107K | 671K | 893K | -1.14M | -4.12M | 215K | 166K |
| Minority Interest | 0 | 0 | 0 | 0 | 110K | -67K | -121K | -224K |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -34.86M | -32.26M | 205.4M | -149.68M | -192.73M | -183.94M | -156.32M | -95.21M |
| Operating CF Margin % | -0.91% | -0.58% | 2.41% | -1.52% | -1.25% | -0.99% | -0.92% | -0.53% |
| Operating CF Growth % | - | 0.07% | 7.37% | -1.73% | -0.29% | 0.05% | 0.15% | 0.39% |
| Net Income | -42.83M | -46.45M | -68.61M | -146.23M | -207.28M | -200.19M | -225.25M | -159.59M |
| Depreciation & Amortization | 5.8M | 6M | 7.79M | 8.47M | 20.98M | 28.15M | 22.23M | 19.26M |
| Stock-Based Compensation | 7.01M | 11.15M | 13.12M | 24.76M | 0 | 0 | 0 | 53.61M |
| Deferred Taxes | 637K | -1.24M | -1.88M | 773K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6K | 5K | 43K | 3.34M | 50.39M | 59.65M | 92.88M | 8.97M |
| Working Capital Changes | -5.47M | -1.72M | 254.93M | -40.8M | -56.82M | -71.55M | -46.18M | -17.45M |
| Change in Receivables | -2.43M | 775K | -7.82M | 2.61M | -7.36M | -22.65M | 2.03M | -3.74M |
| Change in Inventory | -2.7M | -3.05M | -1.23M | -4.99M | -5.2M | 817K | -2.84M | 1.94M |
| Change in Payables | -1.84M | 1.87M | -2.43M | 5.25M | 3.94M | 7.11M | -5.41M | 671K |
| Cash from Investing | 36.43M | 736K | -481.7M | -117.04M | 181.21M | 2.9M | 129.65M | 77.79M |
| Capital Expenditures | -2.51M | -6.32M | -11.2M | -18.8M | -61.75M | -16.35M | -10.7M | -3.66M |
| CapEx % of Revenue | 0.07% | 0.11% | 0.13% | 0.19% | 0.4% | 0.09% | 0.06% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 122K | 19K | -470.5M | -98.24M | 0 | 0 | 0 | 0 |
| Cash from Financing | 50.03M | 1.25M | 319.92M | 293.59M | 27.15M | 132.26M | 2.25M | 241K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 207K | 1.25M | -934K | 21.43M | 429K | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -37.36M | -38.58M | 194.2M | -168.49M | -254.47M | -200.29M | -167.02M | -98.88M |
| FCF Margin % | -0.97% | -0.69% | 2.28% | -1.71% | -1.65% | -1.08% | -0.98% | -0.55% |
| FCF Growth % | - | -0.03% | 6.03% | -1.87% | -0.51% | 0.21% | 0.17% | 0.41% |
| FCF per Share | -0.35 | -0.37 | 1.56 | -1.28 | -1.81 | -1.41 | -1.16 | -0.67 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.69x | -2.99x | 1.02x | 0.93x | 0.92x | 0.69x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -43.85% | -22.25% | -30.77% | -37.48% | -58.33% | -62.45% |
| Return on Invested Capital (ROIC) | - | -14.93% | -15.49% | -18.5% | -24.03% | -28.36% | -41.33% | -41.61% |
| Gross Margin | 59.22% | 64.67% | 73.82% | 77.1% | 68.06% | 68.75% | 55.63% | 59.72% |
| Net Margin | -111.4% | -83.44% | -80.65% | -148.63% | -134.3% | -108.03% | -132.29% | -89.12% |
| Debt / Equity | - | - | 0.06x | 0.15x | 0.18x | 0.23x | 0.32x | 0.44x |
| Interest Coverage | - | - | - | - | - | -47.24x | -16.45x | -14.04x |
| FCF Conversion | 0.81x | 0.69x | -2.99x | 1.02x | 0.93x | 0.92x | 0.69x | 0.60x |
| Revenue Growth | - | 44.77% | 52.83% | 15.65% | 56.88% | 20.06% | -8.11% | 5.1% |
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Sequencing Revenue | 43.52M | 41.44M | 78.9M |
| Sequencing Revenue Growth | - | -4.78% | 90.39% |
| Development Support Revenue | 39.55M | 54.44M | 65.45M |
| Development Support Revenue Growth | - | 37.65% | 20.21% |
| Development Revenue Regulatory Milestones | 2M | 2.5M | 10M |
| Development Revenue Regulatory Milestones Growth | - | 25.00% | 300.00% |
| Development Revenue | 41.55M | 56.94M | - |
| Development Revenue Growth | - | 37.04% | - |
Adaptive Biotechnologies Corporation (ADPT) reported $252.8M in revenue for fiscal year 2024. This represents a 557% increase from $38.4M in 2017.
Adaptive Biotechnologies Corporation (ADPT) grew revenue by 5.1% over the past year. This is steady growth.
Adaptive Biotechnologies Corporation (ADPT) reported a net loss of $79.6M for fiscal year 2024.
Adaptive Biotechnologies Corporation (ADPT) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.
Adaptive Biotechnologies Corporation (ADPT) had negative free cash flow of $62.9M in fiscal year 2024, likely due to heavy capital investments.